Capillary Technologies India Share Price Today (1 December 2025): Post‑IPO Volatility, Analyst Ratings and 2026 Outlook

Updated as of 1 December 2025

Capillary Technologies India share price today

Capillary Technologies India Ltd, recently listed on NSE and BSE under the symbol CAPILLARY, continues to trade with sharp swings in its first few days on the market.

As of 1 December 2025, Capillary Technologies India share price is hovering around ₹620–₹625, down roughly 3–4% intraday. Livemint’s profit-and-loss page shows the stock at about ₹621.25, a fall of 3.7% on the day, with data updated on 1 December 2025. ^[1]

Key trading metrics as of today:

Market cap: roughly ₹5,000–5,100 crore ^[2]
52‑week range:₹570–₹799 – effectively the entire trading history since listing on 21 November 2025 ^[3]
P/E (TTM): around 350–390×
P/B: about 5.6–8× ^[4]
Dividend yield:0% – this is a pure growth play at present ^[5]

The numbers make one thing crystal clear: Capillary Technologies India is trading at a premium valuation by any conventional measure, well above the broader Indian IT / SaaS sector multiples. ^[6]

Quick recap: IPO details and listing day performance

Capillary Technologies India, a Bengaluru‑based SaaS player focused on loyalty and customer engagement, came to the market with an ₹877.5 crore IPO comprising:

Fresh issue: ~₹345 crore
Offer for sale (OFS): ~₹532.5 crore
Price band:₹549–₹577
Lot size: 25 shares (minimum retail application ~₹14,425 at the upper band) ^[7]

The issue saw very strong demand:

Overall subscription: about 53×
QIBs: ~57×
Non‑institutional investors: ~70×
Retail: ~16×
Employee quota: ~7× ^[8]

On 21 November 2025, the listing was, at least initially, underwhelming:

NSE listing: ₹571.90 (0.9% below the issue price of ₹577)
BSE listing: ₹560 (about 3% discount) ^[9]

However, sentiment flipped intraday. Economic Times notes that the stock rallied to around ₹633–634 on both exchanges, up 10–13% from its opening quote. ^[10]

In the days after listing, the stock went on to hit a 52‑week high just below ₹800, before sliding back towards the low‑₹600 zone by 1 December. ^[11]

That’s a ~40% round‑trip swing within less than two weeks of trade — textbook early‑stage IPO volatility.

Business snapshot: what does Capillary actually do?

Capillary Technologies India is not a traditional IT services firm; it’s a software‑product / SaaS company.

Across multiple broker reports and the DRHP, a consistent picture emerges: ^[12]

It offers AI‑driven, cloud‑native loyalty and customer engagement platforms to enterprise clients.
Product suite includes:
- Loyalty+ – design and manage loyalty programmes
- Engage+ – omnichannel customer engagement
- Insights+ – analytics and segmentation
- Rewards+ – catalogue and redemption
- Customer Data Platform (CDP) – unified customer data layer
It serves 400+ brands across 45–47 countries, with presence in India, North America, the Middle East, Southeast Asia, and the UK.
Revenue is largely subscription/usage based, linked to metrics such as loyalty transactions, active members and number of outlets, plus professional services.

Strategically, Capillary positions itself as a picks‑and‑shovels play on global consumer brands trying to increase customer lifetime value via loyalty, personalization, and AI‑driven campaigns.

However, that opportunity comes with two important structural risks repeatedly flagged by analysts:

Client concentration: A small set of large clients contributes a disproportionate share of revenue (top 10 customers >55% in recent periods). ^[13]
Geographic dependence: More than half of revenue now comes from North America, making Capillary exposed to that region’s macro, tech‑spend cycles and FX volatility. ^[14]

Financial performance: from deep losses to thin profits

The core of the Capillary story is a recent, fragile turnaround.

Consolidated financials for the year ended March 2025 (FY25) show: ^[15]

Revenue (FY25): ~₹598 crore
- Up from ~₹525 crore in FY24 (growth ~14%)
EBITDA margin: low double‑digits (~11–16%, depending on the exact definition used by different sources)
Net profit (PAT): ~₹13–14 crore
- Versus a net loss of ~₹59–68 crore in FY24
Net income trend (last four years):
- FY22: ~₹(101) crore loss
- FY23: ~₹(88) crore loss
- FY24: ~₹(59–68) crore loss
- FY25: ~₹14 crore profit ^[16]

IDBI Capital and BP Equities both highlight that FY25 marks the first profitable year after a long stretch of losses, with EBITDA margin swinging from negative to positive as the company scaled revenue and integrated acquisitions. ^[17]

Other notable metrics:

ARR and net revenue retention (NRR): BP Equities notes NRR above 110% over FY23–FY25, with some years closer to 140%, indicating meaningful upsell and cross‑sell to existing customers. ^[18]
Balance sheet: leverage has reduced; total debt has fallen sharply, and the company is effectively near net‑cash by FY25, aided by prior equity raises. ^[19]
Cash flow: despite profitability, FY25 saw negative operating cash flow, which BP Equities flags as a concern given the high valuation. ^[20]

So, the pattern is:

High‑growth SaaS revenue + newly positive margin + still‑fragile cash flows.

Exactly the sort of profile that markets often love — as long as growth and profitability keep trending up.

How expensive is Capillary Technologies India stock?

Let’s talk valuation, because that’s where most of the debate is.

At the IPO price of ₹577, IDBI Capital’s note (using FY25 EPS of about ₹1.9) pegged the issue at roughly 298–300× earnings. ^[21]

Other commentators echo the same ballpark:

Swastika Investmart estimates IPO valuation at around 299× P/E and calls it “aggressively priced” versus global SaaS leaders such as Salesforce and Adobe. ^[22]
BP Equities calculates a P/E of ~302× on FY25 earnings at the upper band and flags negative FY25 operating cash flow. ^[23]

Now that the stock is around ₹620+, and trailing EPS remains tiny, platforms like Groww and Screener still show P/E in the 350–390× range, with P/B well above 5×. ^[24]

Retail‑oriented sites such as shareprice‑target.com note the same FY25 revenue and profit numbers and compute P/E above 320× as of mid‑November. ^[25]

In short:

Capillary Technologies India is priced as a high‑growth, high‑quality SaaS platform, not as a conventional IT services company. Any stumble in growth or margins could trigger a sharp de‑rating.

What are brokers and analysts saying?

Because the listing is very recent, most formal views are IPO‑time recommendations, but they’re still relevant for context today.

IDBI Capital – “SUBSCRIBE (long term)”
IDBI’s IPO note recommends Subscribe for the long term, citing: ^[26]

Capillary’s leadership in enterprise loyalty SaaS
Strong global footprint with 410+ brands across 47 countries
AI‑driven product innovation and scalable cloud infrastructure
Structural demand from digital transformation and customer retention spending

They do, however, acknowledge risks from high customer and geographic concentration.

Arihant Capital – “Neutral”
Arihant assigns a Neutral rating at the IPO, valuing the company at about 7.5× FY25 price‑to‑sales at the upper band. ^[27]

They like:

Market leadership in loyalty and customer engagement
Sticky, recurring SaaS revenue model
Improving profitability

But they flag:

Elevated valuation
Execution risk in new geographies
Client concentration and nascent profit track record

BP Equities – “Avoid”
BP Equities takes a more sceptical stance, rating the IPO “Avoid”. ^[28]

Their key arguments:

P/E around 302× FY25 earnings at the upper band is “expensive”
Negative operating cash flow in FY25
Significant revenue concentration in top customers
Fresh profitability with loss‑making history and still‑evolving subsidiaries

Swastika Investmart – “Avoid”
Swastika’s detailed IPO review also lands on an “Avoid” verdict for conservative investors. ^[29]

They highlight:

Valuation near 299× P/E, far richer than global SaaS giants
High OFS component (over 60% of the issue), with substantial cash going to existing shareholders rather than the company
Client concentration and intense global competition
Thin profitability and modest return ratios (low‑single‑digit ROCE / ROE)

Their conclusion: solid business, excellent theme, but too expensive at issue price for risk‑averse investors.

Value Research – cautious on subdued profitability
Value Research’s IPO analysis emphasises: ^[30]

Subdued profitability despite growth
Heavy reliance on a concentrated set of clients and sectors
Preference, from their advisory lens, for companies with longer and stronger profit track records

The tone is cautious rather than enthusiastic, effectively telling conservative investors not to chase every hot SaaS IPO.

Post‑listing view: INDmoney
After listing, INDmoney’s commentary on Capillary’s weak debut and subsequent jump points out that: ^[31]

The stock listed at a small discount but rallied quickly, reflecting speculative interest.
Valuation remained lofty, with P/E still comfortably above 300× even after initial trading.
Anchor investor lock‑in expiry in “about a month” (around 21 December 2025) could be a volatility trigger if large shareholders choose to book profits.
For long‑term investors, the advice is to watch subsequent results and client wins closely rather than chasing short‑term swings.

Anchor investors and the December lock‑in overhang

Capillary raised roughly ₹394 crore from anchor investors before the IPO, with allocation to a set of domestic and global institutions and mutual funds. ^[32]

While anchor participation signals institutional interest, it also creates a known event:

Anchor shares generally have a 30‑day lock‑in from listing.
For Capillary, that takes you to around 21 December 2025.

IndMoney and other commentators explicitly warn that anchor selling around lock‑in expiry can cause short‑term price dips, especially when the stock has run up sharply from its issue price – which Capillary did when it attempted a near‑₹800 high. ^[33]

For traders, that date is one to mark on the calendar; for long‑term investors, it’s simply one more volatility event to look through.

Latest forecasts and sentiment: what are people expecting now?

Formal 12‑month broker price targets are mostly behind paywalls on sites like Trendlyne and Investing.com, but we can still infer the flavour of the street’s thinking from public data: ^[34]

Multiple domestic brokerages (IDBI, Arihant) see long‑term structural potential, especially if Capillary continues to scale margins from low double‑digits toward more standard SaaS levels. ^[35]
Others (BP Equities, Swastika, Nirman Broking, Value Research) frame it as a “great business, stretched valuation” story and urge caution, particularly for conservative or income‑oriented investors. ^[36]

Retail‑facing blogs such as shareprice‑target.com go a step further and publish multi‑year price targets (2025–2050), projecting substantial upside based mainly on assumed growth and very high P/E multiples. They view Capillary as a potential compounder but clearly note that the company’s fortunes depend heavily on adding customers, maintaining high NRR, and managing concentration risk. ^[37]

Those long‑range targets are not regulated research and should be treated as speculative scenarios rather than reliable forecasts.

Key upside drivers (bull case)

From the more optimistic analyses, the bull case for Capillary Technologies India stock revolves around: ^[38]

Large and growing addressable market
Global brands are shifting budgets from pure customer acquisition to retention and loyalty. That pushes spending towards AI‑driven, data‑heavy platforms like Capillary’s loyalty stack.
High net revenue retention and sticky clients
Net revenue retention above 110% suggests that existing customers expand their spend over time. Combined with high switching costs (deep integration into POS, CRM, and marketing stacks), this creates a favourable land‑and‑expand dynamic.
Global footprint with strong North America growth
Acquisitions in the US and Europe have dramatically increased Capillary’s exposure to developed markets, helping drive revenue growth and higher ticket sizes.
Operating leverage potential
As a SaaS platform, incremental revenue can, in theory, flow through at higher margins once fixed product and infrastructure costs are covered. That’s the logic behind paying high multiples for software platforms.

If revenue growth holds in the mid‑teens or better and margins trend steadily upward, today’s valuation could be justified – that’s the essential bet of the bulls.

Key risks (bear case)

The bear case – again, echoed across multiple broker notes – is that Capillary’s current valuation leaves little room for disappointment. ^[39]

Major risk factors include:

Very high valuation versus fundamentals
P/E in the 300–400× zone and P/S above 7× mean the market already prices in years of strong execution. Any slowdown in revenue, margin pressure or cash‑flow hiccup can trigger sharp de‑rating.
Concentration risk
Losing or downsizing a top client could dent revenue and sentiment. That’s a non‑trivial risk when top 10 customers contribute over half of revenue.
Geographic exposure to North America
A recession, sector‑specific slowdown, or tighter IT budgets in North America would disproportionately hit Capillary compared with more India‑focused IT firms.
Competitive landscape
The company competes directly or indirectly with global heavyweights in martech and loyalty – think Salesforce, Adobe, HubSpot and specialist loyalty platforms. Swastika’s comparison of Capillary’s P/E to those giants underlines the pricing stretch. ^[40]
Execution and integration risk
Capillary has grown partly via acquisitions. Integrating teams, tech stacks and cultures while still delivering margin expansion is non‑trivial.

What does all this mean for investors as of 1 December 2025?

Putting it together:

Capillary Technologies India share price today sits in the low‑₹600s – about 7–8% above the IPO price, but below the near‑₹800 highs hit early last week. ^[41]
The business is attractive: global SaaS, high NRR, AI‑heavy product, blue‑chip clients, and a turnaround to profitability in FY25. ^[42]
The valuation is extreme: three‑digit P/E, rich price‑to‑sales and still‑developing cash flows. ^[43]
Analyst opinion is split: from Subscribe (long term) at IDBI, to Neutral at Arihant, to outright Avoid from BP Equities and Swastika, with Value Research also leaning cautious. ^[44]
An anchor lock‑in expiry around 21 December 2025 hangs over near‑term price action as a potential volatility event. ^[45]

For short‑term traders, Capillary is likely to remain a high‑beta, news‑sensitive stock – driven by flows, anchor activity and sentiment around global SaaS names.

For long‑term, fundamentals‑driven investors, the key questions are simpler and more boring:

Can revenue continue to grow at a healthy clip (mid‑teens or better)?
Do EBITDA and free cash flow margins trend up consistently over the next 3–5 years?
Does client concentration reduce as the customer base broadens?

If the answers are “yes”, early volatility may eventually be forgotten. If not, today’s premium multiples will be hard to defend.

Practical checklist before you touch the stock

This article is not investment advice, but if you’re evaluating Capillary Technologies India as of 1 December 2025, it’s worth:

Reading at least one detailed broker note from each camp – bullish (e.g., IDBI) and cautious (BP, Swastika, Value Research). ^[46]
Tracking upcoming quarterly results and management commentary on growth, margins, and client pipeline.
Watching how the stock behaves around the anchor lock‑in expiry and whether large institutional holders trim or hold. ^[47]
Comparing Capillary’s valuations and metrics with global and Indian SaaS peers, not just traditional IT services companies.

Capillary Technologies India is, in effect, a high‑growth SaaS lottery ticket dressed up as a newly listed midcap. Whether it becomes a long‑term compounding story or a cautionary IPO tale will depend less on today’s share price spikes and more on what its earnings, cash flows and client list look like a few years from now.